CHOP therapy: Has shorter-course therapy had an impact on lymphomas?

Cancer Investigation

Volumn 16, Issue 1, 1998, Pages 26-32

  Gaynor, Ellen R ^a   Fisher, Richard I ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CIMETIDINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RANITIDINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

EID: 0031907094     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809039750     Document Type: Review

References (15)

1. DeVita VT, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC: Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1:248, 1975.
2. Skarin AT, Rosenthal DS, Moloney WC, Frei E: Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). Blood 49:759, 1977.
3. Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Talley R, Butler JJ: Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: a Southwest Oncology Group study. Cancer 51:1083, 1983.
4. Coltman CA, Dahlberg S, Jones SE, Miller TP, Dana BW, Weick JK, McKelvey EM, Hartsock RJ: Southwest Oncology Group studies in diffuse large cell lymphoma: a subset analysis. In: Cancer Chemotherapy: Challenges for the Future, edited by K Kimura, Tokyo, Excerpta Medica, 1988, p 194.
5. O'Reilly SE, Hoskins P, Klimo P, Connors JM: MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 2:17, 1991.
6. Schneider AM, Straus DJ, Schluger AE, Lowenthal DA, Koziner B, Lee BJ, Wong G, Clarkson BD: Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate and some high grade non-Hodgkin's lymphomas. J Clin Oncol 8:94, 1990.
7. Weick JK, Dahlberg S, Fisher RI, Dana B, Miller TP, Balcerzak SP, Pierce HI: Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: A Southwest Oncology Group study. J Clin Oncol 9:748, 1991.
8. Vitolo U, Bertini M, Brusamolino E, Cavallero GB, Comotti B, Gallo E, Ghio R, Levis A, Luxi G, Meneghini V, Novero D, Orsucci L, Rota-Scalabrini D, Tarella C, Todeschini G, Viero P, Barbui T, Bernasconi C, Perona G, Piled A, Resegotti L: MACOP-B treatment in diffuse large-cell lymphoma: Identification of prognostic groups in an Italian multicenter study. J Clin Oncol 10:219, 1992.
9. Fisher RI, DeVita VT, Hubbard SM, Ihde DC, Longo DL, Phares JC, Jaffe ES, Wesley R: Randomized trial of ProMACE-MOPP (day 1, day 8) vs ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc Am Soc Clin Oncol 3:242a, 1984.
10. Fisher RI, De Vita VT, Hubbard SM, Longo DL, Wesley R, Chabner BA, Young RC: Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98:304, 1983.
11. Miller TP, Dahlberg S, Weick JK, Files JC, Eyre HJ, Pendergrass KB, Fisher RI: Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: A groupwide Southwest Oncology Group study. J Clin Oncol 8:1951, 1990.
12. Longo DL, DeVita VT, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI, Young RC: Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 9:25, 1991.
13. Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M, Capnist G, Rossi E, Mangoni L, Fabris P, Vinante O, Tedeschi L, Endrizzi L, Miglio LP, Perrotta A, Rosso R, Damasio E, Rizzoli V: MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group. J Clin Oncol 12:1366, 1994.
14. Cooper IA, Wolf MM, Robertson TI, Fox RM, Matthews JP, Stone JM, Ding JC, Dart G, Matthews J, Firkin FC, Lowenthal RM, Ironside P: Randomized comparison of MACOP-B and CHOP in patients with intermediate grade non-Hodgkin's lymphoma. J Clin Oncol 12:769, 1994.
15. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Eng J Med 328:1002, 1993.